What Is The Current and Historic Market Size Analysis Of The Late Stage Chronic Kidney Disease Drugs Market?
The late stage chronic kidney disease drugs market has seen considerable growth due to a variety of factors.
•There has been a swift expansion in the market size for drugs treating advanced chronic kidney disease in recent years. The market, which stood at $7.08 billion in 2024, is forecasted to escalate to $7.92 billion in 2025, alluding to a compound annual growth rate (CAGR) of 11.9%.
Factors that stimulated the growth during the historic period encompass advancements in diagnostic facilities, a surge in the elderly population, rising cases of diabetes and hypertension, heightened knowledge about kidney ailments and the broadening of pharmaceutical research and development.
What Are The Predictions for The Late Stage Chronic Kidney Disease Drugs Market Size In The Coming Years?
The late stage chronic kidney disease drugs market is expected to maintain its strong growth trajectory in upcoming years.
• In the upcoming years, the market size for drugs treating late stage chronic kidney disease is set to experience a significant surge. It's projected to escalate to $12.2 billion by 2029, with an impressive compound annual growth rate (CAGR) of 11.4%.
Several factors will drive this growth during the projected timeline: an increase in healthcare spending, the implementation of precision medicine strategies, a growing focus on regenerative medicine and patient-centered care, and worldwide efforts to raise awareness about kidney disease. Key trends for this period will be the broadening of regenerative medicine treatments, the upswing in telemedicine services for managing CKD, the evolution of combination therapies, the emphasis on early intervention tactics, and the rising interest in biomarker-based diagnostics.
Which Drivers Are Accelerating Growth In The Late Stage Chronic Kidney Disease Drugs Market?
The escalating occurrence of chronic kidney ailments is believed to bolster the expansion of the drug market dealing with late-stage chronic kidney disorder. These diseases involve a myriad of conditions, impacting the function and structure of the kidneys. Medications for late-stage chronic kidney disease aim to keep a check on the patients' blood pressure and reduce protein loss in order to pause the kidney impairment's progression, oversee the symptoms, and avert any repercussions. For instance, the Centers for Disease Control and Prevention (CDC), a health agency based in the U.S., estimated that in May 2024, approximately 14% of U.S. adults, equating to about 35.5 million individuals, are suspected to be suffering from chronic kidney diseases. Consequently, the rising prevalence of chronic kidney diseases is fueling the growth of the late-stage chronic kidney disease drug market.
What Are The Core Segments Of The Global Late Stage Chronic Kidney Disease Drugs Market?
The late stage chronic kidney disease drugs market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders
2) By Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
Pre-Book The Late Stage Chronic Kidney Disease Drugs Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Trends Are Reshaping The Late Stage Chronic Kidney Disease Drugs Market Size?
Product innovation is emerging as a significant trend in the market for late-stage chronic kidney disease drugs. Major corporations in this market are crafting new drug products to maintain their market standing. For example, Bayer, a pharmaceutical and life sciences company from Germany, introduced Kerendia (finerenone) in India in February 2022. It is recommended for patients with type two diabetes and chronic kidney disease to use finerenone - a pioneering, non-steroidal, selective mineralocorticoid receptor antagonist. This drug functions by precluding excessive activation of the mineralocorticoid receptor (MR), which is believed to be contributing to the onset of chronic kidney disease (CKD) and damage to the cardiovascular system.
Who Are the Key Players in the Late Stage Chronic Kidney Disease Drugs Market?
Major companies operating in the late stage chronic kidney disease drugs market include:
• Pfizer Inc.
• Johnson & Johnson
• AbbVie Inc.
• Bayer AG
• Novartis AG
• Sanofi SA
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Eli Lilly and Company
• C.H. Boehringer Sohn AG & Co. KG
• Amgen Inc.
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Otsuka Pharmaceutical Co. Ltd.
• Takeda Pharmaceutical Company Limited
• Kyowa Kirin Co Ltd.
• OPKO Health Inc.
• Evotec SE
• Ionis Pharmaceuticals Inc.
• Akebia Therapeutics Inc.
• Ardelyx Inc.
• Concert Pharmaceuticals Inc.
• Pharmaxis Limited
• Deltanoid Pharmaceuticals Inc.
• Liminal BioSciences Inc.
• Chinook Therapeutics Inc.
• Allena Pharmaceuticals Inc
• Shield Therapeutics Plc
What are the Regional Insights into the Late Stage Chronic Kidney Disease Drugs Market?
North America was the largest region in the late-stage chronic kidney disease drugs market in 2024. The regions covered in the late-stage chronic kidney disease drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
